Dexmedetomidine Promotes SH-SY5Y Cell Resistance Against Impairment of Iron Overload by Inhibiting NF-κB Pathways
- 27 Downloads
Iron overload is a common pathophysiological state underlying many diseases that has a detrimental influence on cells. The protective effects of Dexmedetomidine (Dex), a high selective alpha-2-adrenoceptor agonist, have been revealed through many experimental models, whereas no study reports its effects on an iron overload model. To elucidate these effects, we used FeCl2 with or without Dex to treat SH-SY5Y cells for 24 h and then detected indicators of oxidative stress, inflammation and apoptosis and investigated possible mechanisms further. After treatment with FeCl2 for 24 h, cell viability decreased in a dose dependent manner, and Dex promoted cell survival in FeCl2 incubation, also in a dose-dependent manner. Compared with the FeCl2 group, 20 µM Dex significantly attenuated ROS accumulation, reduced pro-inflammatory cytokine expression, and inhibited apoptosis. Furthermore, 20 µM concentration of Dex remarkably downregulated the expression of pro-apoptotic protein and activation of caspase 3 while increasing anti-apoptotic protein expression. Additionally, Dex also effectively suppressed the expression of NF-κB and its activation. In conclusion, Dex exerted anti-oxidative stress, anti-inflammation, and anti-apoptosis effects on FeCl2-treated SH-SY5Y cells, possibly by inhibiting NF-κB signaling pathway.
KeywordsIron overload Dexmedetomidine Oxidative stress Inflammation Apoptosis NF-κB
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 23.Hu H, Shi D, Hu C, Yuan X, Zhang J, Sun H (2017) Dexmedetomidine mitigates CLP-stimulated acute lung injury via restraining the RAGE pathway. Am J Transl Res 9:5245–5258Google Scholar
- 24.Liu XR, Li T, Cao L, Yu YY, Chen LL, Fan XH, Yang BB, Tan XQ (2018) Dexmedetomidine attenuates H2O2-induced neonatal rat cardiomyocytes apoptosis through mitochondria- and ER-medicated oxidative stress pathways. Mol Med Rep 17:7258–7264Google Scholar
- 25.Breuer T, Bleilevens C, Rossaint R, Marx G, Gehrenkemper J, Dierksen H, Delpierre A, Weis J, Gayan-Ramirez G, Bruells CS (2018) Dexmedetomidine impairs diaphragm function and increases oxidative stress but does not aggravate diaphragmatic atrophy in mechanically ventilated rats. Anesthesiology 128:784–795CrossRefGoogle Scholar
- 26.Heil LB, Santos CL, Santos RS, Samary CS, Cavalcanti VC, Araujo MM, Poggio H, Maia LA, Trevenzoli IH, Pelosi P, Fernandes FC, Villela NR, Silva PL, Roccoet PR (2016) The effects of short-term propofol and dexmedetomidine on lung mechanics, histology, and biological markers in experimental obesity. Anesth Analg 122:1015–1023CrossRefGoogle Scholar
- 28.Wang K, Li C (2018) Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-kappaB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma. Oncol Lett 15:7153–7157Google Scholar